hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06293768 id: FADOI.05.2018 briefTitle: Continuous Wireless Monitoring for Patients in the Internal Medicine UOC. Randomized Controlled Trial (GreenLineH-T) acronym: GreenLineH-T overallStatus: COMPLETED date: 2019-09-23 date: 2023-12-31 date: 2024-02-20 date: 2024-03-05 date: 2024-03-05 name: Fadoi Foundation, Italy class: OTHER briefSummary: Monocentric prospective controlled randomized in open-label study. The study involves the enrollment of 300 patients (150 patients undergoing continuous monitoring and 150 as a control), aim of the study is to evaluate in these patients the efficacy of a continuous telemonitoring of the patient's clinical condition for 5 days compared to a traditional clinical monitoring. conditions: Hospitalization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The study involves the enrollment of 300 patients (150 patients undergoing continuous monitoring and 150 as a control). 50 of the patients undergoing continuous monitoring come from the group A and 100 from group B, same ratio in the control group.
Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 208 type: ACTUAL name: continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients) measure: difference in the incidence of major complications at 30 days measure: number of acute patients who in seven days reach the criteria to be discharged or ransferred to the subacute ward measure: Difference in the incidence of major complications at the end of the telemonitoring phase sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale di Albano - Polo H2 city: Roma country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06293755 id: COA022/66 briefTitle: Microneedle Patch With Botulinum Toxin in Management of Enlarged Facial Pores overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-28 date: 2024-03-05 date: 2024-06-25 date: 2024-03-05 date: 2024-03-05 name: Dhurakij Pundit University class: OTHER briefSummary: The purpose of this study is to assess the efficacy and safety of microneedle patch with botulinum toxin for improving enlarged pores. conditions: Enlarged Pores studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: Microneedle patch name: Intradermal injection measure: Change from baseline of enlarged pores as measured by VISIA (pores parameter) and using pore score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dhurakij Pundit University city: Lak Si state: Bangkok country: Thailand lat: 13.88724 lon: 100.5792 hasResults: False
nctId: NCT06293729 id: NGGT006-P-2302 briefTitle: Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-31 date: 2029-03-01 date: 2024-03-05 date: 2024-04-17 name: Suzhou Municipal Hospital class: OTHER briefSummary: This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in patients with refractory Hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia. NGGT006 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C). conditions: Refractory Hypercholesterolemia conditions: Familial Hypercholesterolemia studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 9 type: ESTIMATED name: NGGT006 measure: Incidence of treatment-related adverse events (AE) and serious adverse events (SAE) measure: Absolute change and percent change in LDL-C measure: Absolute change and percent change in non-high density lipoprotein cholesterol measure: Absolute change and percent change in apolipoprotein B measure: Absolute change and percent change in total cholesterol measure: Absolute change and percent change in HDL-C measure: Absolute change and percent change in triglycerides measure: Absolute change and percent change in very low-density lipoprotein cholesterol measure: Absolute change and percent change in lipoprotein(a) measure: Absolute change and percent change in apolipoprotein A-I sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06293716 id: CVL237-A2001 briefTitle: CVL237 Tablets for APDS/PASLI overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-12-29 date: 2026-03-30 date: 2024-03-05 date: 2024-03-05 name: Convalife (Shanghai) Co., Ltd. class: INDUSTRY briefSummary: This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency). conditions: PI3K and P110delta Hyperactivation Syndrome studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: CVL237 tablets for APDS/PASLI (Activated phosphoinositol 3-kinase delta syndrome /p110 delta-activated Mutation leading to senescent T cells, lymphadenopathy, and immune deficiency) primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Part II is a randomized, double-blind, placebo-controlled study of approximately 30 patients with APDS/PASLI. On day 1, patients were randomly assigned to the trial and placebo groups in a 2:1 ratio to take an oral CVL237 tablet or a placebo CVL237 simulant once daily. Efficacy and safety were evaluated on days 29, 57, and 85. The efficacy of CVL237 tablets in reducing lymphadyopathy will be investigated as measured by changes in the sum of diameter products (SPD) of target lesions selected from MRI or CT imaging according to the Lugano 2014 method, as well as changes in the percentage of naive B cells to total B cells, relative to baseline. The CVL237 tablets will also be evaluated for safety, PK whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 35 type: ESTIMATED name: CVL237 tablets name: CVL237 placebo tablets measure: part 1 : Incidence of Treatment-Emergent Adverse Events measure: part 2:After 84 days of treatment, changes in the sum of diameter product (SPD) of log10 conversion in target lesions and changes in the percentage of naive B cells to total B cells from baseline were observed measure: Cmax measure: t1/2 measure: AUC measure: Tmax sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Public Health Clinical Center city: Shanghai state: Shanghai zip: 201508 country: China name: Yun Ling, ph.D role: CONTACT phone: 18121157875 email: yun.ling@vip.126.com name: Ying Lv role: CONTACT phone: 18916099680 lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06293703 id: 23-1228 briefTitle: Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study) acronym: CLIMB II overallStatus: RECRUITING date: 2024-01-12 date: 2025-12-11 date: 2030-12-11 date: 2024-03-05 date: 2024-03-05 name: Salvador Navarrete class: OTHER briefSummary: The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics. conditions: Morbid Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study will be a prospective, randomized controlled trial with a 1:1 recruitment allocation ratio coordinated at the Cleveland Clinic Foundation (CCF) primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 262 type: ESTIMATED name: Surgery measure: To determine change in TWL after aRYGB compared to sRYGB in morbidly obese patients measure: To compare rates of DM resolution between aRYGB Vs sRYGB by DM subgroup analysis measure: To investigate postoperative efficacy rates of aRYGB compared to sRYGB on alleviating metabolic syndrome in morbid obesity measure: To investigate the presence of postoperative vitamin and nutritional deficiencies between the groups. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland clinic status: RECRUITING city: Cleveland state: Ohio zip: 44195 country: United States name: Salvador Navarrete, MD role: CONTACT phone: 216-219-9211 email: navarrs@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06293690 id: L23-407 briefTitle: Toripalimab Combined With SBRT for NSCLC overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-06-30 date: 2026-06-30 date: 2024-03-05 date: 2024-03-06 name: Shanghai Pulmonary Hospital, Shanghai, China class: OTHER briefSummary: This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC conditions: Non-small Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Toripalimab name: Toripalimab measure: Major pathological remission rate measure: Complete pathological remission rate measure: disease-free survival（DFS） measure: overall survival measure: Adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Pulmonary Hospital city: Shanghai state: Shanghai zip: 200000 country: China name: Deping Zhao role: CONTACT phone: 0086-20-65115006 email: zdp1992@163.com name: Deping Zhao role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06293677 id: 2023-01013 briefTitle: Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance acronym: DAR-ARC overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03 date: 2026-03 date: 2024-03-05 date: 2024-03-05 name: Centre Hospitalier Universitaire Vaudois class: OTHER name: Unisanté Centre universitaire de médecine générale et santé publique name: FORCE Fondation Recherche sur le Cancer de l'Enfant briefSummary: This clinical trial focuses on children with cancer who face infections after receiving chemotherapy. Chemotherapy affects the bone marrow, leading to a decrease in the production of certain white blood cells, particularly those that defend against bacterial infections (neutrophils). One significant concern is febrile neutropenia, where children experience a fever during a period of low white blood cell count. This condition often results from bacterial infections, necessitating prompt wide-spectrum antibiotic treatment. However, some children eliminate antibiotics in the urine too quickly during febrile neutropenia. Their kidneys function more than they normally do (renal hyperfiltration). This can lead to insufficient exposure to antibiotics to control the infection. The current standard antibiotic regimens do not account for this variable elimination rate. In this study we focus on two antibiotics used in this context: piperacillin-tazobactam and meropenem.
* Would they recover more quickly with higher antibiotic doses? All patients will undergo a blood test upon hospital arrival, including an assessment of renal function. If renal function is normal or diminished, the patient will receive the standard antibiotic dose. Children with increased renal function will be randomly assigned to two groups during each episode of febrile neutropenia. One group will receive standard antibiotic dosages, while the other will receive higher doses to compensate for renal hyperfiltration. Throughout the study, antibiotic levels in the blood will be monitored for all patients. This monitoring will determine if target concentrations can be achieved more quickly with experimental dosages and will allow doctors to readjust the doses if needed. conditions: Febrile Neutropenia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Our study is an open-label, re-randomized controlled trial in multi-episodes settings. So the care team, researchers and patients will be informed of the allocation group. Patients will be able to participate in each episode of febrile neutropenia. At each inclusion the patient may be in a different group. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem name: Standard dosages of piperacillin-tazobactam or meropenem measure: Achievement of antibiotic concentration targets in the intervention group (1i) vs control groupe (1c) measure: Achievement of antibiotic concentration targets in control group 2 measure: Fever duration measure: Side effects of antibiotic therapy measure: Number of dosage adjustments required to achieve the target concentration measure: Difference between eGFR measured by creatinine-based Schwartz formula and other eGFR calculation formulas sex: ALL minimumAge: 61 Days maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Centre Hospitelier Universitaire Vaudois (CHUV) city: Lausanne state: Vaud zip: 1011 country: Switzerland name: Margherita Plebani role: CONTACT phone: +41795563598 email: Margherita.Plebani@chuv.ch name: Pierre-Alex Crisinel role: PRINCIPAL_INVESTIGATOR lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06293664 id: RAHM-2023-006 briefTitle: Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes acronym: α-MSH & T2DM overallStatus: RECRUITING date: 2024-03-04 date: 2024-04-04 date: 2024-04-04 date: 2024-03-05 date: 2024-03-05 name: Dasman Diabetes Institute class: OTHER briefSummary: Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland. It acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus (T2DM). conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The research involves a double-blinded, randomized, placebo-controlled crossover study to assess the therapeutic potential of α-MSH infusion in T2DM patients. primaryPurpose: SCREENING masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 13 type: ESTIMATED name: α-MSH infusion name: Placebo solutions measure: Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion measure: Difference in the total or incremental area under the curve of the concentration of metabolites (C-peptide, Glucagon, Gut hormones, α-MSH) during OGTT with saline or α-MSH infusion. measure: Difference in energy intake measured by an ad libitum meal test at the saline vs. α-MSH infusion measure: Adverse events (including flushing) sex: ALL minimumAge: 21 Years maximumAge: 50 Years stdAges: ADULT facility: Dasman Diabetes Institute status: RECRUITING city: Kuwait City country: Kuwait name: Ebaa Al Ozairi, MD role: CONTACT name: Dalal Alsaeed, PhD role: CONTACT name: Carel Roux, MD role: SUB_INVESTIGATOR lat: 29.36972 lon: 47.97833 hasResults: False
nctId: NCT06293651 id: DA4505_AMST_I/IIa briefTitle: Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-11 date: 2030-04 date: 2024-03-05 date: 2024-03-05 name: Dong-A ST Co., Ltd. class: INDUSTRY briefSummary: This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors. conditions: Locally Advanced or Metastatic Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 125 type: ESTIMATED name: DA-4505 name: DA-4505 + Pembrolizumab measure: Proportion of adverse events (AEs) meeting protocol-defined dose-limiting toxicity(DLT) criteria measure: PK parameters for DA-4505 (Peak Plasma Concentration (Cmax)) measure: PK parameters for DA-4505 (Area Under the Curve (AUC)) measure: PK parameters for DA-4505 (half-life (t1/2)) measure: Response per revised "Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06293638 id: 23-1125 briefTitle: Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor acronym: TRaNCE overallStatus: RECRUITING date: 2024-03-25 date: 2026-12-31 date: 2026-12-31 date: 2024-03-05 date: 2024-04-02 name: The Cleveland Clinic class: OTHER briefSummary: The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation. conditions: Essential Tremor studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Alcohol name: Alprazolam name: Cold Therapy name: Peripheral Nerve Stimulation measure: CTCM Coherence measure: Power of oscillatory activity across the CTCM network in response to tremor interventions measure: Essential tremor severity: Tremor Research Group Essential Tremor Rating Scale (TETRAS) measure: Essential tremor severity: Grip force measure: Essential tremor severity: Limb acceleration sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic status: RECRUITING city: Cleveland state: Ohio zip: 44195 country: United States name: Jeff Negrey, MA role: CONTACT phone: 216-636-5504 email: negreyj2@ccf.org name: James Liao, MD role: PRINCIPAL_INVESTIGATOR name: Ken baker, PhD role: SUB_INVESTIGATOR lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06293625 id: LEPAGE PHRCK 2022-2 briefTitle: Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More acronym: FOxTROT2France overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2032-03 date: 2032-03 date: 2024-03-05 date: 2024-03-05 name: Centre Hospitalier Universitaire Dijon class: OTHER briefSummary: Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp).
FOxTROT 2, a trial to test the role of NAC in older patients. conditions: Colon Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Folfox name: Surgery measure: DFS (disease Free Survival) sex: ALL minimumAge: 70 Years stdAges: OLDER_ADULT facility: CHU Dijon Bourgogne city: Dijon zip: 21000 country: France name: Côme LEPAGE role: CONTACT email: come.lepage@u-bourgogne.fr lat: 47.31667 lon: 5.01667 hasResults: False
nctId: NCT06293612 id: 22/449-3651 id: 2022-I2M-C&T-B-077 type: OTHER_GRANT domain: CAMS Innovation Fund for Medical Sciences (CIFMS) id: 7244398 type: OTHER_GRANT domain: Youth program of Beijing Natural Science Foundation id: Beijing Hope Run Special Fund type: OTHER_GRANT domain: LC2021A12 briefTitle: Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer acronym: MIS-MRC overallStatus: COMPLETED date: 2015-01-01 date: 2018-12-31 date: 2022-11-30 date: 2024-03-05 date: 2024-03-05 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: The goal of this observational study is to construct a multimodal intelligent model to predict the risk of heterochronous metastasis of rectal cancer, which is helpful for individualized diagnosis and treatment and follow-up planning. The main questions it aims to answer are:
This study will not affect or interfere with the routine medical diagnosis and treatment of participants, and will not increase the cost and risk of participants. Participant's information is protected and identified by a unique code. conditions: Locally Advanced Rectal Cancer conditions: Distant Metastasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 302 type: ACTUAL name: No intervention was administrated to the two cohorts. measure: Heterochronous distant metastasis measure: Distant metastasis-free survival sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College city: Beijing zip: 100021 country: China lat: 39.9075 lon: 116.39723 hasResults: False